Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep;33(9):1889-93.
doi: 10.1007/s11064-008-9662-4. Epub 2008 Mar 21.

Plasma catechols in familial dysautonomia: a long-term follow-up study

Affiliations

Plasma catechols in familial dysautonomia: a long-term follow-up study

David S Goldstein et al. Neurochem Res. 2008 Sep.

Abstract

This study tested whether familial dysautonomia (FD) involves progressive loss of noradrenergic nerves. Plasma levels of catechols, including dihydroxyphenylglycol (DHPG), norepinephrine (NE), dopamine (DA), and DOPA, were measured in 7 adult patients with FD and 50 healthy control subjects. FD patients were re-tested after a mean follow-up period of 13 years. Compared to controls, FD patients had low plasma levels of DHPG (P < 0.001), high DOPA and DA levels (P = 0.01, P = 0.0002), and high NE:DHPG (P < 0.0001), DA:NE (P = 0.0003), and DOPA:DHPG (P < 0.0001) ratios. At follow-up there were no changes in plasma levels of individual catechols; however, there were further increases in DOPA:DHPG ratios (mean 24 +/- 7%, P = 0.01). In FD, plasma catechol profiles are sufficiently stable, at least over a decade, to be used as a biomarker of disease involvement. An increasing DOPA:DHPG ratio suggests slight but consistent, progressive loss of noradrenergic neurons.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Individual values for the ratio of plasma dihydroxyphenylalanine (DOPA): dihydroxyphenylglycol (DHPG) as a function of plasma dopamine (DA):norepinephrine (NE) in control subjects (white circles), familial dysautonomia patients upon initial evaluation (gray circles), and familial dysautonomia patients after an interval of 13 years (black circles). Dashed lines placed to emphasize that all familial dysautonomia patients had both high DOPA:DHPG and high DA:NE ratios at both testing times, a finding not observed in any control subjects correlated positively with DA:NE ratios (P = 0.69, P < 0.0001).
Fig. 2
Fig. 2
Individual values for the ratio of plasma dihydroxyphenylalanine (DOPA): dihydroxyphenylglycol (DHPG) in familial dysautonomia patients upon initial evaluation and after an interval of 13 years. Horizontal bars indicate mean values. Gray zone indicates values within 2 standard deviations of the control mean value. Note that all familial dysautonomia patients had an initial DOPA:DHPG ratio more than 2 standard deviations above the control mean and that the patients had a further increase in the DOPA:DHPG ratio at follow-up

Similar articles

Cited by

References

    1. Slaugenhaupt SA, Blumenfeld A, Gill SP, et al. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet. 2001;68:598–605. - PMC - PubMed
    1. Close P, Hawkes N, Cornez I, et al. Transcription impairment and cell migration defects in elongator-depleted cells: implication for familial dysautonomia. Mol Cell. 2006;22:521–531. - PubMed
    1. Pearson J, Pytel BA. Quantitative studies of sympathetic ganglia and spinal cord intermedio-lateral gray columns in familial dysautonomia. J Neurol Sci. 1978;39:47–59. - PubMed
    1. Hilz MJ, Axelrod FB, Bickel A, et al. Assessing function and pathology in familial dysautonomia: assessment of temperature perception, sweating and cutaneous innervation. Brain. 2004;127:2090–2098. - PubMed
    1. Pearson J, Gallo G, Gluck M, et al. Renal disease in familial dysautonomia. Kidney Int. 1980;17:102–112. - PubMed

Publication types